Congestion is the most common reason for admissions and readmissions for heart failure (HF). The vast majority of hospitalized HF patients appear to respond readily to loop diuretics, but available data suggest that a significant proportion are being discharged with persistent evidence of congestion. Although novel therapies targeting congestion should continue to be developed, currently available agents may be utilized more optimally to facilitate complete decongestion. The combination of loop diuretics, natriuretic doses of mineralocorticoid receptor antagonists and vasopressin antagonists represents a regimen of currently available therapies that affects early and persistent decongestion, while limiting the associated risks of electrolyte disturbances, hemodynamic fluctuations, renal dysfunction and mortality.

Vaduganathan, M., Mentz, R., Greene, S., Senni, M., Sato, N., Nodari, S., et al. (2015). Combination decongestion therapy in hospitalized heart failure: Loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 13(7), 799-809 [10.1586/14779072.2015.1053872].

Combination decongestion therapy in hospitalized heart failure: Loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists

Senni M.;
2015

Abstract

Congestion is the most common reason for admissions and readmissions for heart failure (HF). The vast majority of hospitalized HF patients appear to respond readily to loop diuretics, but available data suggest that a significant proportion are being discharged with persistent evidence of congestion. Although novel therapies targeting congestion should continue to be developed, currently available agents may be utilized more optimally to facilitate complete decongestion. The combination of loop diuretics, natriuretic doses of mineralocorticoid receptor antagonists and vasopressin antagonists represents a regimen of currently available therapies that affects early and persistent decongestion, while limiting the associated risks of electrolyte disturbances, hemodynamic fluctuations, renal dysfunction and mortality.
Articolo in rivista - Articolo scientifico
Scientifica
Heart failure; loop diuretics; mineralocorticoid receptor antagonists; neurohormones; Vasopressin antagonists;
English
Vaduganathan, M., Mentz, R., Greene, S., Senni, M., Sato, N., Nodari, S., et al. (2015). Combination decongestion therapy in hospitalized heart failure: Loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 13(7), 799-809 [10.1586/14779072.2015.1053872].
Vaduganathan, M; Mentz, R; Greene, S; Senni, M; Sato, N; Nodari, S; Butler, J; Gheorghiade, M
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/372162
Citazioni
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 9
Social impact